Drugs / COVID-19 mRNA Vaccine (nucleoside modified)
COVID-19 mRNA Vaccine (nucleoside modified)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04969276 | Jul 2021 → Feb 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 mRNA Vaccine (nucleoside modified) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04969276 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273 vaccine booster dose” PMID 35114141 ↗ Feb 2022 |
| Route | Intramuscular | “Intramuscular injection” NCT04969276 ↗ |